NHS to roll out fast‑acting injectable pembrolizumab immunotherapy for thousands of cancer patients
England’s National Health Service announced that an injectable form of the cancer drug pembrolizumab will be offered to thousands of patients each year. The treatment can be administered in under two minutes and works by blocking the PD‑1 protein that hampers the immune response to tumours. Health officials say it will broaden access to life‑extending therapy across multiple cancer types.
Advertisement: Article Inline